CASI Pharmaceuticals Inc (CASI)vsNovartis AG ADR (NVS)
CASI
CASI Pharmaceuticals Inc
$0.21
0.00%
HEALTHCARE · Cap: $4.26M
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 213578% more annual revenue ($57.36B vs $26.85M). NVS leads profitability with a 17.5% profit margin vs -184.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
CASI
Avoid24
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CASI.
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1095.0% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CASI
The strongest argument for CASI centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : CASI
The primary concerns for CASI are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
CASI profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
CASI carries more volatility with a beta of 0.89 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 24/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CASI Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · China
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?